TAKEDA PHARMACEUTICAL CO LTD's ticker is TAK and the CUSIP is 874060205. A total of 3 filers reported holding TAKEDA PHARMACEUTICAL CO LTD in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $988,162 | +9.9% | 63,876 | +11.6% | 0.02% | +16.7% |
| Q2 2023 | $899,366 | -29.1% | 57,248 | -25.6% | 0.02% | -30.8% |
| Q1 2023 | $1,268,268 | +17.0% | 76,958 | +10.8% | 0.03% | +18.2% |
| Q4 2022 | $1,083,779 | +8.1% | 69,473 | -10.2% | 0.02% | +4.8% |
| Q3 2022 | $1,003,000 | +4.4% | 77,360 | +13.1% | 0.02% | +16.7% |
| Q2 2022 | $961,000 | -15.3% | 68,420 | -13.7% | 0.02% | +5.9% |
| Q1 2022 | $1,135,000 | +39.8% | 79,263 | +33.1% | 0.02% | +41.7% |
| Q4 2021 | $812,000 | -21.2% | 59,563 | -5.3% | 0.01% | -25.0% |
| Q3 2021 | $1,030,000 | +14.2% | 62,884 | +17.3% | 0.02% | +23.1% |
| Q2 2021 | $902,000 | +12.8% | 53,607 | +22.4% | 0.01% | +8.3% |
| Q1 2021 | $800,000 | +79.4% | 43,796 | +78.6% | 0.01% | +71.4% |
| Q4 2020 | $446,000 | +48.2% | 24,528 | +45.3% | 0.01% | +16.7% |
| Q3 2020 | $301,000 | +246.0% | 16,878 | +247.7% | 0.01% | +200.0% |
| Q2 2020 | $87,000 | – | 4,854 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Adelphi Capital LLP | 7,584,930 | $138,046,000 | 26.79% |
| Glenview Capital Management | 15,260,512 | $277,741,000 | 6.37% |
| Paulson & Co. | 11,295,846 | $205,584,000 | 5.34% |
| GMT CAPITAL CORP | 2,871,395 | $52,259,000 | 3.72% |
| MANAGED ASSET PORTFOLIOS, LLC | 966,643 | $17,593,000 | 3.09% |
| TFG Asset Management GP Ltd | 1,443,052 | $26,264,000 | 1.76% |
| Mondrian Investment Partners LTD | 3,274,660 | $58,944,000 | 1.46% |
| Blackcrane Capital, LLC | 35,236 | $641,000 | 1.26% |
| Lumbard & Kellner, LLC | 136,378 | $2,404,000 | 0.95% |
| DAVIDSON INVESTMENT ADVISORS | 509,800 | $9,278,000 | 0.86% |